Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
100%
Chemotherapy
54%
Oxaliplatin
48%
Cetuximab
36%
Overall Survival
34%
Neoplasm
29%
Irinotecan
29%
Colorectal Carcinoma
29%
Pancreas Cancer
26%
Bevacizumab
19%
Fluorouracil
19%
Capecitabine
18%
Malignant Neoplasm
17%
Peritoneum Metastasis
16%
Progression Free Survival
16%
Biological Marker
15%
Disease
11%
Abdominal Cancer
9%
Pancreas Adenocarcinoma
9%
Clinical Trial
9%
Folinic Acid
8%
Esophagus Cancer
7%
Gemcitabine
7%
Frailty
7%
Monotherapy
7%
Epidermal Growth Factor Receptor
7%
Trifluridine
7%
Tipiracil
7%
Carcinoembryonic Antigen
7%
Phase II Trials
6%
C Reactive Protein
6%
Epirubicin
6%
Cisplatin
6%
Solid Malignant Neoplasm
6%
Rectum Cancer
5%
microRNA
5%
Pembrolizumab
5%
Fluoropyrimidine
5%
Primary Tumor
5%
Paclitaxel
5%
Adverse Event
5%
Adenocarcinoma
5%
Tolerability
5%
Medicine and Dentistry
Chemotherapy
64%
Metastatic Colorectal Cancer
54%
Pancreas Cancer
37%
Overall Survival
36%
Colorectal Carcinoma
28%
Neoplasm
27%
Oxaliplatin
23%
Peritoneum Metastasis
21%
Malignant Neoplasm
16%
Disease
15%
Pancreas Adenocarcinoma
15%
Rectum Cancer
14%
Irinotecan
13%
Surgery
13%
Systemic Therapy
12%
Fluorouracil
11%
Frailty
11%
Clinical Trial
10%
Progression Free Survival
10%
Quality of Life
9%
Geriatric Assessment
9%
Radiation Therapy
9%
Adjuvant Chemotherapy
9%
Biological Marker
9%
Gemcitabine
9%
Capecitabine
8%
Adenocarcinoma
8%
Colon Carcinoma
7%
Pembrolizumab
7%
Carcinoembryonic Antigen
7%
Abdominal Cancer
7%
Recurrent Disease
7%
Chemoradiotherapy
7%
Randomized Controlled Trial
7%
Oncology
6%
Geriatrics
6%
Hazard Ratio
6%
Combination Chemotherapy
6%
Cell-Free DNA
5%
Bevacizumab
5%
Primary Tumor
5%
Metastatic Carcinoma
5%
Folinic Acid
5%
Trifluridine
5%
Tipiracil
5%
Diagnosis
5%
Gastrointestinal Cancer
5%
Prognostic Factor
5%
Fluoropyrimidine
5%